Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionPanagora Asset Management Inc
Latest Disclosed Ownership592,912 shares
Latest Disclosed Value $ 17,615,416
Panagora Asset Management Inc reports 0.95% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 14, 2026 - Panagora Asset Management Inc filed a 13F-HR form disclosing ownership of 592,912 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $17,615,416 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 587,354 shares of Travere Therapeutics, Inc.. This represents a change in shares of 0.95% during the quarter. The current value of the position is $26,799,622 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 592,912 5,558 0.95 17,615 -21.51 0.0660
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 587,354 17,659 3.10 22,443 64.83 0.0795
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 569,695 137,674 31.87 13,616 112.97 0.0549
2025-08-13 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 432,021 96,062 28.59 6,394 6.20 0.0288
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 335,959 797 0.24 6,020 3.12 0.0301
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 335,162 14,829 4.63 5,839 30.28 0.0270
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 320,333 229,452 252.48 4,481 499.87 0.0214
2024-07-29 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 90,881 90,881 747 0.0038
2024-05-07 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 0 -84,909 -100.00 0 -100.00
2024-02-08 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 84,909 -167,389 -66.35 763 -66.16 0.0043
2023-10-31 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 252,298 -40,084 -13.71 2,256 -49.78 0.0140
2023-08-11 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 292,382 90,385 44.75 4,491 -1.14 0.0265
2023-05-12 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 201,997 100,465 98.95 4,543 112.74 0.0287
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 101,532 101,532 2,135 0.0140
2021-11-10 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 0 -19 -100.00 0 0.0000
2021-08-11 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 19 -541 -96.61 0 -100.00
2021-05-12 2021-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 560 -44,609 -98.76 14 -98.86 0.0001
2021-02-10 2020-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 45,169 -120,374 -72.71 1,231 -59.72 0.0073
2020-11-13 2020-09-30 13F RETROPHIN COMMON 761299106 165,543 -93,173 -36.01 3,056 -42.12 0.0191
2020-08-12 2020-06-30 13F RETROPHIN COMMON 761299106 258,716 12,164 4.93 5,280 46.79 0.0337
2020-05-14 2020-03-31 13F RETROPHIN COMMON 761299106 246,552 -315,718 -56.15 3,597 -54.95 0.0254
2020-02-12 2019-12-31 13F RETROPHIN COMMON 761299106 562,270 105,198 23.02 7,984 50.73 0.0363
2019-11-12 2019-09-30 13F RETROPHIN COMMON 761299106 457,072 2,880 0.63 5,297 -41.95 0.0244
2019-08-09 2019-06-30 13F RETROPHIN COMMON 761299106 454,192 47,870 11.78 9,125 -0.76 0.0408
2019-05-15 2019-03-31 13F RETROPHIN COMMON 761299106 406,322 218,006 115.77 9,195 115.74 0.0409
2019-02-14 2018-12-31 13F RETROPHIN COMMON 761299106 188,316 133,406 242.95 4,262 170.09 0.0198
2018-11-13 2018-09-30 13F RETROPHIN COMMON 761299106 54,910 54,910 1,578 0.0059
2017-05-15 2017-03-31 13F RETROPHIN COMMON 761299106 0 -32,235 -100.00 0 -100.00
2017-02-14 2016-12-31 13F RETROPHIN COMMON 761299106 32,235 27,886 641.20 610 528.87 0.0028
2016-11-14 2016-09-30 13F RETROPHIN COMMON 761299106 4,349 1,974 83.12 97 130.95 0.0005
2016-08-15 2016-06-30 13F RETROPHIN COMMON 761299106 2,375 0 0.00 42 31.25 0.0002
2016-05-16 2016-03-31 13F RETROPHIN COMMON 761299106 2,375 -1,354 -36.31 32 -54.93 0.0002
2016-02-12 2015-12-31 13F RETROPHIN COMMON 761299106 3,729 1,500 67.29 71 69.05 0.0003
2015-11-13 2015-09-30 13F RETROPHIN COMMON 761299106 2,229 -356 -13.77 42 -49.40 0.0002
2015-08-14 2015-06-30 13F RETROPHIN COMMON 761299106 2,585 2,585 83 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.